Electropharmacology sells SofPulse to ADM:
This article was originally published in Clinica
Executive Summary
Electropharmacology has sold the assets in SofPulse, a palliative pain treatment device, to ADM Tronics, a Northvale, New Jersey company making its first entry into the US devices market. The SofPulse divestiture is the first stage in Pompano Beach, Florida-based Electropharmacology's plan to restructure around the Pulsed Electromagnetic Signals (PEMS) technology, aimed at "large markets such as cancer, inflammation and tissue regeneration". ADM plans to expand distribution of SofPulse in the US and to target present distributors of its Sonotron device outside the US. SofPulse last year generated revenues of $1.5 million.